Clinical Trial Update: Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Nal-IRI plus 5-FU with standard 5-FU in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma Advanced
• Cholangiocarcinoma Metastatic
• Cholangiocarcinoma Non-resectable
• Cholangiocarcinoma of the Gallbladder

Drugs mentioned

• 5-FU (5-fluorouracil)
• Nal-IRI (nanoliposomal irinotecan)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Status: COMPLETED